BLA 021172 · Novo Nordisk INC
Novolog Mix 70/30 Penfill
Insulin Aspart Protamine Recombinant, Insulin Aspart Recombinant · Subcutaneous · Insulin Analog
Priority reviewLast checked: Nov 20, 2026Latest source record: Feb 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2001
Nov 1, 2001
Approved uses
4
Original approval plus efficacy supplements
Registered trials
99
28 Phase 3, 0 recruiting
FAERS reports
12,980
10,763 serious, 1,506 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 18, 2026.
NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine and insulin aspart indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: NOVOLOG MIX 70/30 is not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins in NOVOLOG MIX 70/30 are fixed and do not allow for basal versus prandial dose adjustments. NOVOLOG MIX 70/30 is a mixture of insulin aspart protamine, an intermediate-acting human insulin analog, and insulin aspart, a rapid-acting human insulin analog, indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis. The proportions of rapid-acting and long-acting insulins are fixed and do not allow for basal versus prandial dose adjustments (1) .
Mechanism: The primary activity of insulin, including NOVOLOG MIX 70/30 is the regulation of glucose metabolism. Insulin and its analog lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 7, 2010 Supplement 49 · Efficacy LabelLetter
- May 7, 2010 Supplement 45 · Efficacy LabelLetter
- Nov 21, 2005 Supplement 21 · Efficacy LetterLabel
- Nov 1, 2001 Original approval · Type 4 - New Combination · priority review LetterLabelReview
4 products under this application
- NOVOLOG MIX 70/30 PENFILL · INSULIN ASPART PROTAMINE RECOMBINANT 210 UNITS/3ML; INSULIN ASPART RECOMBINANT 90 UNITS/3ML (70 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Discontinued
- NOVOLOG MIX 70/30 · INSULIN ASPART PROTAMINE RECOMBINANT 700 UNITS/10ML; INSULIN ASPART RECOMBINANT 300 UNITS/10ML (70 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Prescription
- NOVOLOG MIX 70/30 FLEXPEN · INSULIN ASPART PROTAMINE RECOMBINANT 210 UNITS/3ML; INSULIN ASPART RECOMBINANT 90 UNITS/3ML (70 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Prescription
- NOVOLOG MIX 70/30 PENFILL · INSULIN ASPART PROTAMINE RECOMBINANT 210 UNITS/3ML; INSULIN ASPART RECOMBINANT 90 UNITS/3ML (70 UNITS/ML · INJECTABLE, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Aspart Protamine Recombinant" as an intervention, any sponsor and status, largest first.
- INITIATE Plus (INITiation of Insulin to Reach A1c TargEt) StudyPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00101751 · 4,877 participants · Start Oct 2004 · Primary completion Jun 2006
Drug: biphasic insulin aspart · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Princeton, New Jersey
- Comparison of Insulin Detemir, Insulin Aspart and Biphasic Insulin Aspart 30 With OAD Treatment in Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00184600 · 708 participants · Start Nov 2004 · Primary completion Aug 2009
Drug: biphasic insulin aspart; insulin detemir and 1 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Dublin, Ireland; Galway, Ireland; Aberdeen, United Kingdom · 63 sites in all
Mannkind CorporationIndustry
NCT00309244 · 677 participants · Start Feb 2006 · Primary completion Aug 2008
Drug: Technosphere® Insulin Inhalation Powder; 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) · For: Diabetes Type 2
Sites: Mobile, Alabama; Tucson, Arizona; Chula Vista, California · 151 sites in all
- Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01520818 · 666 participants · Start Mar 2000 · Primary completion Apr 2001
Drug: biphasic insulin aspart 50; biphasic insulin aspart 70 and 1 more · For: Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Sites: Aalst, Belgium; Brussels, Belgium; Edegem, Belgium · 77 sites in all
- Comparison of Biphasic Insulin Aspart 70/30, 50/50, and 30/70 in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00184574 · 603 participants · Start Apr 2005 · Primary completion Mar 2006
Drug: biphasic insulin aspart; metformin · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Bregenz, Austria; Feldkirch, Austria; Graz, Austria · 108 sites in all
- Insulin Glargine "All to Target" TrialPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00384085 · 588 participants · Start May 2006 · Primary completion Mar 2010
Drug: Insulin Glulisine; Insulin Glargine and 2 more · For: Diabetes Mellitus, Type 2
Sites: Bridgewater, New Jersey
- Treatment Intensification With Biphasic Insulin Aspart 30 in Subjects With Type 2 Diabetes Inadequately Controlled on Sitagliptin and MetforminPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT01519674 · 582 participants · Start Jun 2012 · Primary completion Oct 2013
Drug: biphasic insulin aspart 30; biphasic insulin aspart 30 and 2 more · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Buenos Aires, Argentina; Caba, Argentina; Mar del Plata, Argentina · 69 sites in all
- Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 DiabetesPivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02762578 · 543 participants · Start May 3, 2016 · Primary completion May 19, 2017
Drug: insulin degludec/insulin aspart; biphasic insulin aspart · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Hefei, China; Beijing, China; Chongqing, China · 42 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased1,265
- nausea839
- dyspnoea793
- hypoglycaemia737
- vomiting698
- off label use645
- drug ineffective532
- diarrhoea522
- condition aggravated504
- abdominal pain500
- fatigue486
- dizziness451
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 65 |
| 2005 | 95 |
| 2006 | 155 |
| 2007 | 243 |
| 2008 | 313 |
| 2009 | 308 |
| 2010 | 215 |
| 2011 | 236 |
| 2012 | 280 |
| 2013 | 225 |
| 2014 | 277 |
| 2015 | 515 |
| 2016 | 526 |
| 2017 | 573 |
| 2018 | 670 |
| 2019 | 622 |
| 2020 | 790 |
| 2021 | 1,050 |
| 2022 | 1,158 |
| 2023 | 1,047 |
| 2024 | 1,159 |
| 2025 | 1,440 |
| 2026 | 1,018 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Novolog Mix 70-30 (Insulin Aspart Prot/Insuln Asp)
2024 spending
$11.4M
Beneficiaries
12,616
49,697 claims
Per beneficiary
$905
$6.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $112,025,124 |
| 2021 | $91,396,260 |
| 2022 | $77,996,678 |
| 2023 | $66,766,546 |
| 2024 | $11,420,216 |
Part D: Novolog Mix 70-30 Flexpen (Insulin Aspart Prot/Insuln Asp)
2024 spending
$66.9M
Beneficiaries
58,653
241,710 claims
Per beneficiary
$1,140
$8.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $421,364,939 |
| 2021 | $386,853,952 |
| 2022 | $357,828,485 |
| 2023 | $335,124,166 |
| 2024 | $66,851,234 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Novo Nordisk · Also marketed as Novolog Mix 70/30, Novolog Mix 70/30 Flexpen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.